196 related articles for article (PubMed ID: 38718699)
1. Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis.
Felício de Campos E; Xavier CB; Queiroz MM; Firmino Lima Júnior N; Ilario EN; Coelho RF; Nahas WC; Bastos DA; Fontes Jardim DL
Clin Genitourin Cancer; 2024 Jun; 22(3):102088. PubMed ID: 38718699
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
3. Perioperative Morbidity of Radical Prostatectomy After Intensive Neoadjuvant Androgen Blockade in Men With High-Risk Prostate Cancer: Results of Phase II Trial Compared to a Control Group.
Ilario EN; Bastos DA; Guglielmetti GB; Murta CB; Cardili L; Cordeiro MD; Junior JP; Coelho RF; Nahas WC
Clin Genitourin Cancer; 2023 Feb; 21(1):43-54. PubMed ID: 36428171
[TBL] [Abstract][Full Text] [Related]
4. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Rajwa P; Pradere B; Gandaglia G; van den Bergh RCN; Tsaur I; Shim SR; Yanagisawa T; Laukhtina E; Mori K; Mostafaei H; Quhal F; Bryniarski P; Compérat E; Roubaud G; Massard C; Merseburger AS; Leapman MS; Spratt DE; Saad F; Joniau S; D'Amico AV; Briganti A; Shariat SF; Ploussard G;
Eur Urol; 2022 Jul; 82(1):82-96. PubMed ID: 35465985
[TBL] [Abstract][Full Text] [Related]
5. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
6. Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis.
Katayama S; Mori K; Pradere B; Mostafaei H; Schuettfort VM; Quhal F; Motlagh RS; Laukhtina E; Grossmann NC; Rajwa P; Aydh A; König F; Mathieu R; Nyirady P; Karakiewicz PI; Nasu Y; Shariat SF
Scand J Urol; 2022 Apr; 56(2):85-93. PubMed ID: 35142251
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients.
Jin C; Fan Y; Meng Y; Shen C; Wang Y; Hu S; Cui C; Xu T; Yu W; Jin J
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):333-339. PubMed ID: 27595915
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
McClintock TR; von Landenberg N; Cole AP; Lipsitz SR; Gild P; Sun M; Fletcher SA; Roghmann F; Menon M; Nguyen PL; Noldus J; Choueiri TK; Kibel AS; Trinh QD
Ann Surg Oncol; 2019 Jan; 26(1):297-305. PubMed ID: 30430324
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review.
Devos G; Vansevenant B; De Meerleer G; Clinckaert A; Devlies W; Claessens F; Graefen M; Steuber T; Briganti A; de la Taille A; Van Poppel H; Joniau S
World J Urol; 2021 Sep; 39(9):3177-3185. PubMed ID: 33580296
[TBL] [Abstract][Full Text] [Related]
11. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
[TBL] [Abstract][Full Text] [Related]
12. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
Nguyen PL; Je Y; Schutz FA; Hoffman KE; Hu JC; Parekh A; Beckman JA; Choueiri TK
JAMA; 2011 Dec; 306(21):2359-66. PubMed ID: 22147380
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review.
Yanagisawa T; Rajwa P; Quhal F; Kawada T; Bekku K; Laukhtina E; Deimling MV; Chlosta M; Karakiewicz PI; Kimura T; Shariat SF
J Pers Med; 2023 Apr; 13(4):. PubMed ID: 37109028
[TBL] [Abstract][Full Text] [Related]
14. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Philippou YA; Kuntz GM; Konety BR; Gupta S; Lamb AD; Dahm P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012816. PubMed ID: 30320443
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
16. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
18. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis.
Spratt DE; Malone S; Roy S; Grimes S; Eapen L; Morgan SC; Malone J; Craig J; Dess RT; Jackson WC; Hartman HE; Kishan AU; Mehra R; Kaffenberger S; Morgan TM; Reichert ZR; Alumkal JJ; Michalski J; Lee WR; Pisansky TM; Feng FY; Shipley W; Sandler HM; Schipper MJ; Roach M; Sun Y; Lawton CAF
J Clin Oncol; 2021 Jan; 39(2):136-144. PubMed ID: 33275486
[TBL] [Abstract][Full Text] [Related]
19. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol.
Calleris G; Filleron T; Kesch C; Roubaud G; Pradère B; Cabarrou B; Malavaud B; Roupret M; Mourey L; Ploussard G
Eur Urol Oncol; 2024 Jun; 7(3):494-500. PubMed ID: 37806843
[TBL] [Abstract][Full Text] [Related]
20. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
